Hyperactivity News and Research

RSS

New system that reduces ADHD symptoms in children to be rolled out across the UK

A new thought-operated computer system which can reduce the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in children will be rolled out across the UK this month.

7 Jan 2010

Study shows prevalence of SED remains high after Hurricane Katrina

A team made up of mental health professionals, emergency response experts, and researchers from several universities, including Virginia Tech, has published the results of a study that shows serious emotional disturbances among children who were affected by Hurricane Katrina.

6 Jan 2010

Ben-Gurion University researcher defines integrated interpretation of ASD

A researcher from Ben-Gurion University of the Negev has defined a new, integrated interpretation of Autism Spectrum Disorders (ASD), which makes it easier to understand both the commonalities and differences between ASD and other conditions.

5 Jan 2010

Ligand Pharmaceuticals acquires Neurogen

Ligand Pharmaceuticals Incorporated announced today that it has completed the acquisition of Neurogen Corporation, following approval of the transaction by Neurogen stockholders earlier today. As a result, Ligand gains a fully funded partnership with Merck & Co., additional pipeline assets, drug discovery resources and additional cash balances.

23 Dec 2009

ADHD Support Twitter page from Shire

Shire plc, the global specialty biopharmaceutical company, announced the launch of its newest online Attention-Deficit/Hyperactivity Disorder (ADHD) resource, the ADHD Support Twitter(TM) page (http://twitter.com/adhdsupport), derived from the Shire award-winning online educational resource, ADHDSupport.com.

22 Dec 2009

Investigational study of TRT to alleviate debilitating effects of tinnitus commenced

A University of Alabama researcher is embarking on a $5.6 million phase-three, randomized, controlled clinical trial to evaluate the effectiveness of an innovative treatment that uses a noise-generating device, along with counseling, to alleviate the debilitating effects of tinnitus - that ringing in the ears that drives some people to distraction.

17 Dec 2009

Diet rich in omega-3 fatty acids linked to improved nervous-system function

The omega-3 essential fatty acids commonly found in fatty fish and algae help animals avoid sensory overload, according to research published by the American Psychological Association.

17 Dec 2009

Survey provides comprehensive look at prevalence of common mental disorders

Only about half of American children and teenagers who have certain mental disorders receive professional services, according to a nationally representative survey funded in part by the National Institute of Mental Health (NIMH). The survey also provides a comprehensive look at the prevalence of common mental disorders.

14 Dec 2009

Children exposed to tobacco smoke prenatally develop behavioral problems, shows study

The scientists observed that the impact of tobacco smoke was especially detrimental during gestation. The results of the study have been published in the current online issue of the renowned journal Environmental Health Perspectives.

10 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.

3 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

MRI pioneer honored with MRC Millennium Medal

Sir Peter Mansfield, The University of Nottingham's Nobel Laureate for Physiology and Medicine, is to be recognised, once again, for his part in one of the most important breakthroughs in medical science.

2 Dec 2009

New research shows hyperactivity in boys may interfere with night-time sleep

Hyperactive boys don't get enough sleep, which can worsen their condition according to new research. Published in the November issue of Pediatrics, the study is the first to examine a large sample of children and to study the link between lack of sleep and hyperactivity.

1 Dec 2009

Findings show the relationship between neurotransmitter dopamine and ADHD

Scientists at the California Institute of Technology (Caltech) have uncovered evidence of a primitive emotion-like behavior in the fruit fly, Drosophila melanogaster.

26 Nov 2009

New report finds positive association between phthalate exposure and ADHD symptoms

Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Studies to date on phthalates have been inconsistent, with some linking exposure to these chemicals to hormone disruptions, birth defects, asthma, and reproductive problems, while others have found no significant association between exposure and adverse effects.

19 Nov 2009

Shire publishes new study results on INTUNIV Extended-Release Tablets

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone.

17 Nov 2009

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Sciele Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd. and Addrenex Pharmaceuticals, Inc., a privately-held U.S. pharmaceutical company specializing in developing drugs that regulate the adrenergic system, today announced that Sciele has agreed to acquire Addrenex.

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

Poor mental health in children and teenagers impacts on the length of time they will stay in school: Study

"Our study shows that poor mental health in children and teenagers has a large impact on the length of time they will stay in school," says Dr. Lehrer. He notes a large number of school-based programs have recently been introduced to prevent childhood obesity through lifestyle changes, but suggests the net should be cast more widely. "It's important for policymakers to target health conditions that are not the easiest to identify - like inattention - but may have larger impacts on one's future."

13 Nov 2009

Hyperactivity News and Research

New system that reduces ADHD symptoms in children to be rolled out across the UK

Study shows prevalence of SED remains high after Hurricane Katrina

Ben-Gurion University researcher defines integrated interpretation of ASD

Ligand Pharmaceuticals acquires Neurogen

ADHD Support Twitter page from Shire

Investigational study of TRT to alleviate debilitating effects of tinnitus commenced

Diet rich in omega-3 fatty acids linked to improved nervous-system function

Survey provides comprehensive look at prevalence of common mental disorders

Children exposed to tobacco smoke prenatally develop behavioral problems, shows study

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

MRI pioneer honored with MRC Millennium Medal

New research shows hyperactivity in boys may interfere with night-time sleep

Findings show the relationship between neurotransmitter dopamine and ADHD

New report finds positive association between phthalate exposure and ADHD symptoms

Shire publishes new study results on INTUNIV Extended-Release Tablets

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Poor mental health in children and teenagers impacts on the length of time they will stay in school: Study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News